209808-47-9
209808-47-9 结构式
基本信息
ARM-390HCl
AR-M1000390 HCl
ARM390 Hydrochloride
ARM 390
ARM-390
ARM390
AR-M 1000390 hydrochloride
N,N-Diethyl-4-(phenyl-4-piperidinylideneMethyl)benzaMide Hydrochloride
N,N-Diethyl-4-(phenyl(piperidin-4-ylidene)methyl)benzamide hydrochloride
Benzamide,N,N-diethyl-4-(phenyl-4-piperidinylidenemethyl)-,monohydrochloride
N,N-Diethyl-4-[phenyl(4-piperidinylidene)methyl]benzamide hydroch loride (1:1)
物理化学性质
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/04/30 | HY-101039A | ARM-390HCL AR-M 1000390 hydrochloride | 209808-47-9 | 5mg | 990元 |
| 2024/04/30 | HY-101039A | ARM-390HCL AR-M 1000390 hydrochloride | 209808-47-9 | 10mM * 1mLin DMSO | 1089元 |
| 2024/04/30 | HY-101039A | ARM-390HCL AR-M 1000390 hydrochloride | 209808-47-9 | 10 mg | 1700元 |
常见问题列表
EC50: 7.2±0.9 nM (δ opioid receptor)
AR-M 1000390 (Compound 6a) exhibits the binding affinities (IC 50 ) of 0.87±0.23 nM for the δ opioid receptor and extremely high selectivity over the µ receptor (IC 50 =3800±172 nM) and the κ receptor (IC 50 =7470±606 nM). RINm5F cells are treated with AR-M 1000390 (AR-M100390) and Cyclizine for 16-24 h before measurement of intracellular and secreted insulin levels. AR-M 1000390 mediates a dose-dependent decrease in insulin content with a maximal inhibition of ~90% at the highest concentration tested (10 μM).
Rats are treated with 5, 100, and 600 μmol/kg of AR-M 1000390 (AR-M100390) for 3 and/or 7 days; another group of rats treated with 600 μmol/kg of compound are allowed to recover for 14 days. AR-M 1000390 (600 μmol/kg) causes vacuolation in the β-cell of the rat pancreas that is associated with depletion of insulin and hyperglycemia after 7 days of dosing. Treatment of rats with 600 μmol/kg of AR-M 1000390 results in vacuolation of the β-cell of the rat pancreas that is similar to that reported for cyclizine and cyproheptadine.